-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Docetaxel and abiraterone acetate in combination with prednisone or prednisone (AAP) can improve the survival rate of patients with locally advanced or metastatic hormone-sensitive prostate cancer when started together with standard care (SOC) androgen deprivation therapy
In the STAMPEDE trial, a group of patients were enrolled at the same time and randomly received docetaxel + SOC or AAP + SOC
Changes in overall QOL scores of patients in the two treatment groups
Changes in overall QOL scores of patients in the two treatment groupsA total of 515 patients were included: 173 received docetaxel + SOC, and 342 received AAP + SOC
In the two years of randomization, the average modeled overall QOL score of patients receiving AAP+SOC treatment was 3.
Compared with docetaxel + standard androgen deprivation therapy, patients with locally advanced or metastatic hormone-sensitive prostate cancer treated with abiraterone acetate combined with prednisone or prednisone + standard androgen deprivation therapy within two years Reported quality of life is better.
Original source:
Hannah L.
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
in this message